EC Number | Application | Comment | Organism |
---|---|---|---|
2.3.1.31 | medicine | using a mouse inhalation model of infection it is shown that MET2 is required for virulence, making fungal HTA a viable target for new antibiotic discovery | Cryptococcus neoformans |
EC Number | Cloned (Comment) | Organism |
---|---|---|
2.3.1.31 | expressed in Escherichia coli as a His-tagged fusion protein | Cryptococcus neoformans |
EC Number | Protein Variants | Comment | Organism |
---|---|---|---|
2.3.1.31 | additional information | Met auxotrophy is shown by a constructed MET2 mutant and its growth behavior in Met-deficient media | Cryptococcus neoformans |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
2.3.1.31 | 6-carbamoyl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid | competitive inhibitor of acetyl-CoA | Cryptococcus neoformans |
EC Number | KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|---|
2.3.1.31 | additional information | - |
additional information | kcat/Km (substrate L-homoserine): 130000/Msec, (substrate acetyl-CoA): 878000/Msec | Cryptococcus neoformans |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
2.3.1.31 | Cryptococcus neoformans | - |
- |
- |
EC Number | Purification (Comment) | Organism |
---|---|---|
2.3.1.31 | using Ni-NTA chromatography | Cryptococcus neoformans |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.3.1.31 | acetyl-CoA + L-homoserine | - |
Cryptococcus neoformans | CoA + O-acetyl-L-homoserine | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
2.3.1.31 | CnHTA | - |
Cryptococcus neoformans |
2.3.1.31 | homoserine transacetylase | - |
Cryptococcus neoformans |
2.3.1.31 | MET2 | - |
Cryptococcus neoformans |
EC Number | Turnover Number Minimum [1/s] | Turnover Number Maximum [1/s] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|---|
2.3.1.31 | 122 | - |
L-homoserine | - |
Cryptococcus neoformans |
EC Number | pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|---|
2.3.1.31 | 8 | - |
assay at | Cryptococcus neoformans |
EC Number | Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
---|---|---|---|---|---|---|
2.3.1.31 | 0.0136 | - |
6-carbamoyl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid | Ki value of competitive inhibition of acetyl-CoA | Cryptococcus neoformans | |
2.3.1.31 | 0.0917 | - |
6-carbamoyl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid | Ki value of noncompetitive inhibition of L-homoserine | Cryptococcus neoformans |
EC Number | IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|---|
2.3.1.31 | 0.156 | - |
in the presence of 0.01 mM acetyl-CoA | Cryptococcus neoformans | 6-carbamoyl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid | |
2.3.1.31 | 0.287 | - |
in the presence of 0.1 mM acetyl-CoA | Cryptococcus neoformans | 6-carbamoyl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid |